Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial - Vermeire, S; Schreiber, S; Petryka, R (Lancet, 2017)
et al.